CALGARY, Alberta, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals Ltd. (TSX.V:VM, USA:VYYRF) (the “Company” or “Voyageur”) is pleased to announce the fully-integrated iodine business ...
Positive feedback received after completion of CDC tests on 24 subjects All key product performance milestones met or exceeded expectations Voyageur believes it is now a player in the contrast media ...
Voyageur announced on January 13, 2025 (Testing) that the company commenced testing of its current barium contrast media formulations in human subjects, to ensure efficacy and safety in clinical ...
Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved E-Z-HD (barium sulfate) for oral suspension for use in double-contrast radiographic examinations of the esophagus, ...
Bracco Diagnostics announced that the FDA has approved a New Drug Application (NDA) for READI-CAT 2 and READI-CAT 2 SMOOTHIE (barium sulfate) oral suspension for use in computed tomography (CT) of the ...
Contrast agents like barium and iodine, which increase the visibility of medical imaging, are suffering from a global shortage, opening the growing US$6.3 billion dollar market up to new players ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback